510 related articles for article (PubMed ID: 30975542)
1. Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis.
Grootens J; Ungerstedt JS; Ekoff M; Rönnberg E; Klimkowska M; Amini RM; Arock M; Söderlund S; Mattsson M; Nilsson G; Dahlin JS
EBioMedicine; 2019 May; 43():150-158. PubMed ID: 30975542
[TBL] [Abstract][Full Text] [Related]
2. Characterization of CD34
Mayado A; Teodosio C; Dasilva-Freire N; Jara-Acevedo M; Garcia-Montero AC; Álvarez-Twose I; Sánchez-Muñoz L; Matito A; Caldas C; Muñoz-González JI; Henriques A; Sánchez-Gallego JI; Escribano L; Orfao A
Allergy; 2018 Jun; 73(6):1294-1304. PubMed ID: 29331029
[TBL] [Abstract][Full Text] [Related]
3. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.
Teodosio C; García-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Sánchez-Muñoz L; Almeida J; Morgado JM; Matito A; Escribano L; Orfao A
Leukemia; 2012 May; 26(5):951-8. PubMed ID: 22051531
[TBL] [Abstract][Full Text] [Related]
4. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
5. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.
Garcia-Montero AC; Jara-Acevedo M; Teodosio C; Sanchez ML; Nunez R; Prados A; Aldanondo I; Sanchez L; Dominguez M; Botana LM; Sanchez-Jimenez F; Sotlar K; Almeida J; Escribano L; Orfao A
Blood; 2006 Oct; 108(7):2366-72. PubMed ID: 16741248
[TBL] [Abstract][Full Text] [Related]
6. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
[TBL] [Abstract][Full Text] [Related]
7. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
8. CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.
Greiner G; Witzeneder N; Berger A; Schmetterer K; Eisenwort G; Schiefer AI; Roos S; Popow-Kraupp T; Müllauer L; Zuber J; Sexl V; Kenner L; Sperr WR; Valent P; Mayerhofer M; Hoermann G
Blood; 2017 Jan; 129(3):371-382. PubMed ID: 27856463
[TBL] [Abstract][Full Text] [Related]
9. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
10. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis.
Wilson TM; Maric I; Simakova O; Bai Y; Chan EC; Olivares N; Carter M; Maric D; Robyn J; Metcalfe DD
Haematologica; 2011 Mar; 96(3):459-63. PubMed ID: 21134978
[TBL] [Abstract][Full Text] [Related]
11. Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis.
Hoermann G; Cerny-Reiterer S; Perné A; Klauser M; Hoetzenecker K; Klein K; Müllauer L; Gröger M; Nijman SM; Klepetko W; Valent P; Mayerhofer M
Am J Pathol; 2011 May; 178(5):2344-56. PubMed ID: 21457934
[TBL] [Abstract][Full Text] [Related]
12. Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.
Baumgartner C; Cerny-Reiterer S; Sonneck K; Mayerhofer M; Gleixner KV; Fritz R; Kerenyi M; Boudot C; Gouilleux F; Kornfeld JW; Sillaber C; Moriggl R; Valent P
Am J Pathol; 2009 Dec; 175(6):2416-29. PubMed ID: 19893034
[TBL] [Abstract][Full Text] [Related]
13. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
14. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.
Jawhar M; Schwaab J; Schnittger S; Sotlar K; Horny HP; Metzgeroth G; Müller N; Schneider S; Naumann N; Walz C; Haferlach T; Valent P; Hofmann WK; Cross NC; Fabarius A; Reiter A
Leukemia; 2015 May; 29(5):1115-22. PubMed ID: 25567135
[TBL] [Abstract][Full Text] [Related]
15. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.
Fritsche-Polanz R; Fritz M; Huber A; Sotlar K; Sperr WR; Mannhalter C; Födinger M; Valent P
Mol Oncol; 2010 Aug; 4(4):335-46. PubMed ID: 20471335
[TBL] [Abstract][Full Text] [Related]
16. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J
Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453
[TBL] [Abstract][Full Text] [Related]
18. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
[TBL] [Abstract][Full Text] [Related]
19. Mastocytosis.
Metcalfe DD
Novartis Found Symp; 2005; 271():232-42; discussion 242-9. PubMed ID: 16605139
[TBL] [Abstract][Full Text] [Related]
20. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.
Jara-Acevedo M; Teodosio C; Sanchez-Muñoz L; Álvarez-Twose I; Mayado A; Caldas C; Matito A; Morgado JM; Muñoz-González JI; Escribano L; Garcia-Montero AC; Orfao A
Mod Pathol; 2015 Aug; 28(8):1138-49. PubMed ID: 26067933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
